Company profile

Tasly Pharmaceutical Group

Traditional Chinese medicine, cardiovascular franchise

600535 · SSE · China

Public Market Listing

600535SSE

SSE primary exchange listing

Live quotes, historical charts, and market capitalization for Tasly Pharmaceutical Group are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(4 total)
4Total Assets
0Approved
0Phase 3 / Filed
4Phase 1–2 / Early
2Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
B1962
Phase 2
PD-L1 / VEGFMultispecific antibody
Non-Small Cell Lung Cancer
HucMSC intramyocardial therapy
Phase 2
Cardiac cell therapyCell therapy
Heart Failure
Jia Shen Tablet
Phase 2
Multi-target (ginsenoside)Botanical
Heart Failure
QiShenYiQi
Phase 2
Multi-target (ginsenoside)Botanical
Heart Failure

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.